Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in CRISPR Therapeutics AG, CareDx or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how CRISPR Therapeutics AG, CareDx and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About CRISPR Therapeutics AG, CareDx and Inc.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Latest Biotechnology and CRISPR Therapeutics AG, CareDx, Inc. Stock News

As of August 7, 2026, CRISPR Therapeutics AG had a $5.2 billion market capitalization, compared to the Biotechnology median of $271.6 million. CRISPR Therapeutics AG’s stock is up 1.6% in 2026, up 7.5% in the previous five trading days and down 5.01% in the past year.

Currently, CRISPR Therapeutics AG does not have a price-earnings ratio. CRISPR Therapeutics AG’s trailing 12-month revenue is $13.4 million with a % net profit margin. As of August 7, 2026, CRISPR Therapeutics AG has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.474 per share for the current fiscal year. CRISPR Therapeutics AG does not currently pay a dividend.

As of August 7, 2026, CareDx, Inc. had a $2.4 billion market cap, putting it in the 56th percentile of all stocks. CareDx, Inc.’s stock is up 146.2% in 2026, down 3.1% in the previous five trading days and up 256.41% in the past year.

Currently, CareDx, Inc.’s price-earnings ratio is 22.0. CareDx, Inc.’s trailing 12-month revenue is $458.1 million with a 24.2% net profit margin. Year-over-year quarterly sales growth most recently was 52.1%. Analysts expect adjusted earnings to reach $1.213 per share for the current fiscal year. CareDx, Inc. does not currently pay a dividend.

How We Compare CRISPR Therapeutics AG, CareDx and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at CRISPR Therapeutics AG, CareDx and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

CRISPR Therapeutics AG, CareDx and Inc. Growth Grades

Company	Ticker	Growth
CRISPR Therapeutics AG	CRSP	F
CareDx, Inc.	CDNA	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

CRISPR Therapeutics AG has a Growth Score of 7, which is Very Weak. CareDx, Inc. has a Growth Score of 43, which is Average.

The Growth Stock Winner: No Clear Winner

Neither CRISPR Therapeutics AG, CareDx or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if CRISPR Therapeutics AG, CareDx or Inc. is the better investment when it comes to sustainable growth.

CRISPR Therapeutics AG, CareDx and Inc.’s Quality Grades

Company	Ticker	Quality
CRISPR Therapeutics AG	CRSP	F
CareDx, Inc.	CDNA	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

CRISPR Therapeutics AG has a Quality Score of 9, which is Very Weak. CareDx, Inc. has a Quality Score of 97, which is Very Strong.

The Quality Grade Winner: CareDx, Inc.

As you can clearly see from the Quality Grade breakdown above, CareDx, Inc. has a better overall quality grade than CRISPR Therapeutics AG. For investors who are looking for companies with higher quality than others in the same industry, CareDx, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

CRISPR Therapeutics AG, CareDx and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
CRISPR Therapeutics AG	CRSP	C
CareDx, Inc.	CDNA	A

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

CRISPR Therapeutics AG has a Earnings Estimate Score of 59, which is Neutral. CareDx, Inc. has a Earnings Estimate Score of 92, which is Very Positive.

The Earnings Estimate Revisions Grade Winner: CareDx, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, CareDx, Inc. has a better Earnings Estimate Revisions Grade than CRISPR Therapeutics AG. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, CareDx, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other CRISPR Therapeutics AG, CareDx and Inc. Grades

In addition to Estimate Revisions, Quality and Growth, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether CRISPR Therapeutics AG, CareDx and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, CRISPR Therapeutics AG, CareDx or Inc. Stock?

Overall, CRISPR Therapeutics AG stock has a Growth Score of 7, Estimate Revisions Score of 59 and Quality Score of 9.

CareDx, Inc. stock has a Growth Score of 43, Estimate Revisions Score of 92 and Quality Score of 97.

Comparing CRISPR Therapeutics AG, CareDx and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.